Search Results - "Boumpas, D T"

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs by Bertsias, G K, Ioannidis, J P A, Aringer, M, Bollen, E, Bombardieri, S, Bruce, I N, Cervera, R, Dalakas, M, Doria, A, Hanly, J G, Huizinga, T W J, Isenberg, D, Kallenberg, C, Piette, J C, Schneider, M, Scolding, N, Smolen, J, Stara, A, Tassiulas, I, Tektonidou, M, Tincani, A, van Buchem, M A, van Vollenhoven, R, Ward, M, Gordon, C, Boumpas, D T

“…To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations. The authors…”
Get more information

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics by Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Gordon, C, Boumpas, D T

“…Systemic lupus erythematosus (SLE) is a complex disease with variable presentations, course and prognosis. We sought to develop evidence-based recommendations…”
Get more information

Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative by Gossec, L, Paternotte, S, Aanerud, G J, Balanescu, A, Boumpas, D T, Carmona, L, de Wit, M, Dijkmans, B A C, Dougados, M, Englbrecht, M, Gogus, F, Heiberg, T, Hernandez, C, Kirwan, J R, Mola, E Martin, Cerinic, M Matucci, Otsa, K, Schett, G, Scholte-Voshaar, M, Sokka, T, von Krause, G, Wells, G A, Kvien, T K

“…A patient-derived composite measure of the impact of rheumatoid arthritis (RA), the rheumatoid arthritis impact of disease (RAID) score, takes into account…”
Get more information

Sexual dimorphism in SLE: above and beyond sex hormones by Christou, Evangelos A A, Banos, Aggelos, Kosmara, Despoina, Bertsias, George K, Boumpas, Dimitrios T

“…Systemic lupus erythematosus (SLE) is characterized by aberrant production of auto-antibodies and a sexual dimorphism both in the phenotypic expression and…”
Get full text

Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative by Gossec, L, Dougados, M, Rincheval, N, Balanescu, A, Boumpas, D T, Canadelo, S, Carmona, L, Daurès, J-P, de Wit, M, Dijkmans, B A C, Englbrecht, M, Gunendi, Z, Heiberg, T, Kirwan, J R, Mola, E M, Matucci-Cerinic, M, Otsa, K, Schett, G, Sokka, T, Wells, G A, Aanerud, G J, Celano, A, Dudkin, A, Hernandez, C, Koutsogianni, K, Akca, F N, Petre, A-M, Richards, P, Scholte-Voshaar, M, Von Krause, G, Kvien, T K

“…Current response criteria in rheumatoid arthritis (RA) usually assess only three patient-reported outcomes (PROs): pain, functional disability and patient…”
Get more information

Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis by Kastrinaki, M-C, Sidiropoulos, P, Roche, S, Ringe, J, Lehmann, S, Kritikos, H, Vlahava, V-M, Delorme, B, Eliopoulos, G D, Jorgensen, C, Charbord, P, Häupl, T, Boumpas, D T, Papadaki, H A

“…Bone marrow (BM) mesenchymal stem cells (MSCs) are being considered as potential therapeutic agents in various inflammatory autoimmune diseases for their…”
Get more information

Inflammasomes and rheumatic diseases: evolving concepts by Sidiropoulos, P I, Goulielmos, G, Voloudakis, G K, Petraki, E, Boumpas, D T

“…The realisation that the production of inflammatory cytokines in inflammatory rheumatic diseases may be induced by non-infectious endogenous signals has…”
Get more information

Regional european genetic ancestry predicts type I interferon level and risk of severe viral infection by Nln, Ilona, Shum, Justine, Ghodke-Puranik, Yogita, Tipon, Regine, Triese, Danielle, Amin, Shreyasee, Makol, Ashima, Osborn, Thomas, Chowdhary, Vaidehi, Thanarajasingam, Uma, Wampler Muskardin, Theresa L, Oke, Vilija, Gunnarsson, Iva, Zickert, Agneta, Zervou, Maria I, Boumpas, Dimitrios T, Svenungsson, Elisabet, Goulielmos, George N, Niewold, Timothy B

“…Viral infection outcomes vary widely between individuals, ranging from mild symptoms to severe organ failure and death, and it is clear that host genetic…”
Get full text

Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study by Karvounaris, S A, Sidiropoulos, P I, Papadakis, J A, Spanakis, E K, Bertsias, G K, Kritikos, H D, Ganotakis, E S, Boumpas, D T

“…Objectives: Patients with rheumatoid arthritis have an increased risk for cardiovascular disease (CVD). The prevalence of metabolic syndrome (MetS)—a major…”
Get full text

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis by ILLEI, Gabor G, AUSTIN, Howard A, KLIPPEL, John H, BALOW, James E, BOUMPAS, Dimitrios T, CRANE, Marianna, COLLINS, Lee, GOURLEY, Mark F, YARBORO, Cheryl H, VAUGHAN, Ellen M, KUROIWA, Takashi, DANNING, Carol L, STEINBERG, Alfred D

“…Controlled trials in lupus nephritis have demonstrated that cyclophosphamide therapy is superior to corticosteroid therapy alone. The long-term effectiveness…”
Get full text

Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists by Sidiropoulos, P. I., Hatemi, G., Song, I.-H., Avouac, J., Collantes, E., Hamuryudan, V., Herold, M., Kvien, T. K., Mielants, H., Mendoza, J. M., Olivieri, I., Østergaard, M., Schachna, L., Sieper, J., Boumpas, D. T., Dougados, M.

“…Objective. Recommendations and/or guidelines represent a popular way of integrating evidence-based medicine into clinical practice. The 3E Initiatives is a…”
Get full text

S01.1 Extramedullary hematopoiesis and immune training contribute to tissue inflammation in sle by providing inflammatory license to bone marrow-derived hematopoietic stem and progenitor cells (HSPCS) by Zervopoulou, E, Doumas, S, Banos, A, Gakiopoulou, H, Mitroulis, I, Boumpas, DT, Grigoriou, M

“…PurposeWe have previously shown dysregulation of hematopoiesis in the bone marrow (BM) in SLE, with skewing towards the myeloid lineage and evidence for…”
Get full text

Investigation of the genetic overlap between rheumatoid arthritis and psoriatic arthritis in a Greek population by Myrthianou, E, Zervou, MI, Budu-Aggrey, A, Eliopoulos, E, Kardassis, D, Boumpas, DT, Kougkas, N, Barton, A, Sidiropoulos, P, Goulielmos, GN

“…Objectives: Several rheumatoid arthritis (RA) susceptibility loci have also been found to be associated with psoriatic arthritis (PsA), demonstrating that…”
Get full text

Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease by ANTONIOU, K. M, MAMOULAKI, M, MALAGARI, K, KRITIKOS, H. D, BOUROS, D, SIAFAKAS, N. M, BOUMPAS, D. T

“…To study the potential effectiveness of tumor necrosis factor a (TNF-alpha) inhibitor treatment for pulmonary fibrosis associated with a collagen vascular…”
Get full text

Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response by Papadimitraki, ED, Tzardi, M, Bertsias, G, Sotsiou, E, Boumpas, DT

“…Toll-like receptors recognising self-derived nucleic acids may participate in the pathogenesis of autoimmune diseases. Following the description of an enhanced…”
Get full text

Podocyte main slit diaphragm proteins, nephrin and podocin, are affected at early stages of lupus nephritis and correlate with disease histology by Perysinaki, GS, Moysiadis, DK, Bertsias, G, Giannopoulou, I, Kyriacou, K, Nakopoulou, L, Boumpas, DT, Daphnis, E

“…Renal podocytes and their slit diaphragms ensure the integrity of the renal basement membrane that forms the barrier to urinary protein loss. A putative…”
Get full text

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints by Bertsias, G K, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Boumpas, D T, Gordon, C

“…To assess available evidence on the use of end-points (outcome measures) in clinical trials in systemic lupus erythematosus (SLE), as a part of the development…”
Get more information

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus by Gordon, C, Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostál, C, Font, J, Gilboe, I-M, Houssiau, F, Huizinga, T W J, Isenberg, D, Kallenberg, C G M, Khamashta, M A, Piette, J-C, Schneider, M, Smolen, J S, Sturfelt, G, Tincani, A, Van Vollenhoven, R, Boumpas, D T

“…Systemic lupus erythematosus (SLE) is a complex multi-organ disease, characterised by relapses and remissions. ng a high-quality randomised controlled trial…”
Get more information

Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit by Sidiropoulos, P, Bertsias, G, Kritikos, H D, Kouroumali, H, Voudouris, K, Boumpas, D T

“…Background: Randomised controlled trials have shown that treatment with anti-tumour necrosis factor (anti-TNF) agents is effective in refractory rheumatoid…”
Get full text

Association of the PTPN22 R620W polymorphism with increased risk for SLE in the genetically homogeneous population of Crete by Eliopoulos, E, Zervou, MI, Andreou, A, Dimopoulou, K, Cosmidis, N, Voloudakis, G, Mysirlaki, H, Vazgiourakis, V, Sidiropoulos, P, Niewold, TB, Boumpas, DT, Goulielmos, GN

“…Autoimmune diseases affect approximately 5% of the population, but much work remains to define the genetic risk factors and pathogenic mechanisms underlying…”
Get full text